Progression of malignant pleural effusion during the early stage of gefitinib treatment in advanced EGFR-mutant lung adenocarcinoma involving complex driver gene mutations

Signal Transduct Target Ther. 2020 May 27;5(1):63. doi: 10.1038/s41392-020-0161-7.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma of Lung* / diagnostic imaging
  • Adenocarcinoma of Lung* / drug therapy
  • Adenocarcinoma of Lung* / genetics
  • Adenocarcinoma of Lung* / metabolism
  • ErbB Receptors / genetics
  • ErbB Receptors / metabolism
  • Female
  • Gefitinib* / administration & dosage
  • Gefitinib* / adverse effects
  • Humans
  • Lung Neoplasms* / diagnostic imaging
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / metabolism
  • Male
  • Mutation*
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / metabolism
  • Pleural Effusion, Malignant* / chemically induced
  • Pleural Effusion, Malignant* / diagnostic imaging
  • Pleural Effusion, Malignant* / genetics
  • Pleural Effusion, Malignant* / metabolism
  • Retrospective Studies

Substances

  • Neoplasm Proteins
  • EGFR protein, human
  • ErbB Receptors
  • Gefitinib